Lipedema: what the research says

There are many myths about lipedema online and few reliable summaries of the evidence. On this page we have collected what is known from scientific publications, clinical guidelines and international consensus statements. Every figure links to its original source, and you will find detailed explanations in our articles.

Lipedema in numbers

• ≈10%of women, or roughly one in ten — the most frequently cited estimate of lipedema prevalenceIn the 2026 consensus, estimates reach 12%
• 18 yearson average from the first symptoms to a diagnosisNetherlands, 2018
• 60–80%of patients have relatives with similar changesReview of family data, 2024
• 48%noticed the first symptoms at pubertyUSA, 707 women, 2024
• 68% vs 8%had a meaningful reduction in pain 12 months after liposuction vs conservative therapyLIPLEG, The Lancet, 2026
• 12 yearsimprovement after liposuction is maintained in the longest follow-upGermany, 2021

For more on prevalence and where the “one in three women” myth comes from, see “How common is lipedema?”.

Lipedema research is growing

Scientific publications on lipedema by year

Number of PubMed records with lipedema in the title, abstract or subject headings

1. 2000
6. 2005
11. 122010
16. 2015
21. 582020
26. 119
27. 1752026*

Chart data

Year	Publications
2000	5
2001	2
2002	2
2003	2
2004	7
2005	3
2006	4
2007	5
2008	10
2009	10
2010	12
2011	6
2012	11
2013	15
2014	11
2015	13
2016	19
2017	29
2018	34
2019	31
2020	58
2021	50
2022	63
2023	88
2024	83
2025	119
2026*	175

In the first ten months of 2026, more scientific papers on lipedema were published than in the whole of 2025. At the same time, as of October 2026, PubMed contains no lipedema study from Ukraine.

Key statements of the 2026 international consensus

In January 2026, Nature Communications published the Lipedema World Alliance position paper. It was agreed by experts from 19 countries using the Delphi method, and 59 of the 62 proposed statements reached consensus [1]. Here are the most important ones in our summary:

No.	Consensus statement
1	Lipedema is a chronic disease.
2	Untreated lipedema typically presents as symmetrical, bilateral enlargement of subcutaneous adipose tissue in the extremities, accompanied by pain and/or discomfort.
5	Lipedema typically spares the hands and feet.
10	Patients with lipedema often experience easy bruising in affected areas.
17	Hormonal changes may trigger or exacerbate the symptoms of lipedema.
19	The exact prevalence of lipedema in adult women is unknown; estimates reach 12%.
21	Lipedema is not an obesity-related comorbidity.
22	BMI has limited value in distinguishing lipedema from obesity; the waist-to-height ratio is advisable.
29	Missed or delayed diagnosis worsens symptoms, mental well-being and quality of life.
31	The diagnosis of lipedema is clinical: medical history, examination and exclusion of other conditions.
32	No imaging, blood or genetic tests are officially approved to confirm the diagnosis.
42	Conservative management should include lifestyle and nutritional optimisation, compression and exercise.
50	There is currently no evidence that any medication is effective in treating lipedema.
51	When lipedema coexists with obesity and metabolic disease, these should be treated before surgery is considered.
52	Lymph-sparing surgery should be considered when it can improve lipedema symptoms.
53	Surgery should be performed by specialists with extensive knowledge of lipedema, including conservative treatment.

The numbers follow the numbering in the original publication.

Key studies

Year	Study	What it showed	Our article
2026	LIPLEG, randomised, 410 patients, The Lancet [2]	At 12 months, pain fell meaningfully in 68% after liposuction vs 8% with conservative therapy; serious adverse events 7.5% vs 3.4%	Liposuction: what the research shows
2021	60 patients followed for 12 years after liposuction [7]	Improvements in pain, swelling, bruising and mobility lasted 12 years	Liposuction: what the research shows
2024	Randomised diet trial, 70 women [8]	A low-carbohydrate diet reduced pain more than a standard diet, regardless of weight loss	Diet and lipedema
2024	Survey of 707 women in the USA [9]	Symptoms most often start at puberty (48%) or in pregnancy (41%); 52% saw no benefit from diet and exercise	Causes of lipedema
2025	Prospective cohort, 100 patients, 4.6 years [12]	Lipedema was stable in 62% and progressed in 28%; progression was linked to weight gain and a larger waist	Treatment without surgery
2024	Family genetic study [11]	Family history in 60–80% of patients; no single gene — genetic causes differ	Causes of lipedema
2018	Patient survey in the Netherlands [10]	18 years from symptoms to diagnosis; pain in 88%, bruising in 86%	How common is lipedema?

Guidelines and consensus statements

• Lipedema World Alliance international consensus, 2026 — 59 statements on definition, diagnosis and management [1].
• German S2k guideline, 2024 — 60 recommendations on diagnosis, conservative and surgical treatment, psychosocial aspects and self-management [3].
• US standard of care, 2021 — 85 consensus statements [4].
• Brazilian Delphi consensus on lipedema, 2025 [5].
• Italian consensus on exercise in lipedema, 2024 [6].
• WHO ICD-11: a separate code, EF02.2 “Lipoedema”, since 1 January 2022 [13].
• Germany, G-BA, 2025: liposuction for lipedema is covered by statutory health insurance at any stage, after 6 months of conservative therapy [14].

Our articles

• How common is lipedema? What the studies say and where the “one in three women” myth comes from
• Causes of lipedema: hormones, genetics and inflammation
• Diagnosing lipedema: criteria, ultrasound and why BMI is misleading
• Treating lipedema without surgery: compression, lymphatic drainage and exercise
• Diet and lipedema: what clinical trials show
• Liposuction for lipedema: from 12-year follow-up to LIPLEG in The Lancet
• Lipedema or obesity: 6 differences

How we select sources and review our content is described in our editorial policy.